Patient characteristics
| Variables . | Letermovir (n = 56) . | Control (n = 93) . | P* . |
|---|---|---|---|
| Age, median (range) | 53.9 (19.5-74.1) | 53.2 (19.9-73.2) | .72 |
| Sex, n (%) | |||
| Male | 35 (63) | 56 (60) | .78 |
| Female | 21 (38) | 37 (40) | |
| Cell source, n (%) | |||
| BM/cord | 11 (20) | 12 (13) | .27 |
| PBSC | 45 (80) | 81 (87) | |
| HLA matching, n (%) | |||
| Matched related | 12 (21) | 31 (33) | .29 |
| Matched unrelated | 31 (55) | 45 (48) | |
| Other | 13 (23) | 17 (18) | |
| Donor CMV serostatus, n (%) | |||
| Negative | 40 (71) | 57 (61) | .21 |
| Positive | 16 (29) | 36 (39) | |
| Underlying disease | |||
| AML/ALL | 29 (52) | 31 (33) | .03 |
| Other | 27 (48) | 62 (67) | |
| Conditioning, n (%) | |||
| Myeloablative | 34 (61) | 48 (52) | <.001 |
| Nonmyeloablative | 8 (14) | 38 (41) | |
| Reduced intensity | 14 (25) | 7 (8) | |
| ALC (cells per mm3), n (%) | |||
| ≤300 | 14 (25) | 12 (13) | .06 |
| >300 | 42 (75) | 81 (87) | |
| Acute GVHD, n (%) | |||
| Grade 0-1 | 18 (32) | 32 (34) | .78 |
| Grade 2-4 | 38 (68) | 61 (66) | |
| HCT Risk-type, n (%) | |||
| High | 17 (30.4) | 22 (23.7) | .44 |
| Low | 39 (69.6) | 71 (76.3) | |
| Steroid AUC by day 100 (mg/kg per day), median (range) | 25.6 (6.5-104.3) | 30.1 (4.8-193.6) | .14 |
| Peak CMV DNAemia by day 100 (log10 IU/mL), median (range) | 0.0 (0.0-3.6) | 2.3 (0.0-4.5) | <.001 |
| CMV shedding rate by day 100 (% PCR with detectable CMV DNA), median (range) | 0.0 (0.0-0.7) | 0.3 (0.0-0.9) | <.001 |
| Variables . | Letermovir (n = 56) . | Control (n = 93) . | P* . |
|---|---|---|---|
| Age, median (range) | 53.9 (19.5-74.1) | 53.2 (19.9-73.2) | .72 |
| Sex, n (%) | |||
| Male | 35 (63) | 56 (60) | .78 |
| Female | 21 (38) | 37 (40) | |
| Cell source, n (%) | |||
| BM/cord | 11 (20) | 12 (13) | .27 |
| PBSC | 45 (80) | 81 (87) | |
| HLA matching, n (%) | |||
| Matched related | 12 (21) | 31 (33) | .29 |
| Matched unrelated | 31 (55) | 45 (48) | |
| Other | 13 (23) | 17 (18) | |
| Donor CMV serostatus, n (%) | |||
| Negative | 40 (71) | 57 (61) | .21 |
| Positive | 16 (29) | 36 (39) | |
| Underlying disease | |||
| AML/ALL | 29 (52) | 31 (33) | .03 |
| Other | 27 (48) | 62 (67) | |
| Conditioning, n (%) | |||
| Myeloablative | 34 (61) | 48 (52) | <.001 |
| Nonmyeloablative | 8 (14) | 38 (41) | |
| Reduced intensity | 14 (25) | 7 (8) | |
| ALC (cells per mm3), n (%) | |||
| ≤300 | 14 (25) | 12 (13) | .06 |
| >300 | 42 (75) | 81 (87) | |
| Acute GVHD, n (%) | |||
| Grade 0-1 | 18 (32) | 32 (34) | .78 |
| Grade 2-4 | 38 (68) | 61 (66) | |
| HCT Risk-type, n (%) | |||
| High | 17 (30.4) | 22 (23.7) | .44 |
| Low | 39 (69.6) | 71 (76.3) | |
| Steroid AUC by day 100 (mg/kg per day), median (range) | 25.6 (6.5-104.3) | 30.1 (4.8-193.6) | .14 |
| Peak CMV DNAemia by day 100 (log10 IU/mL), median (range) | 0.0 (0.0-3.6) | 2.3 (0.0-4.5) | <.001 |
| CMV shedding rate by day 100 (% PCR with detectable CMV DNA), median (range) | 0.0 (0.0-0.7) | 0.3 (0.0-0.9) | <.001 |
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BM, bone marrow; PBSC, peripheral blood stem cell.
Fisher’s exact test or Wilcoxon rank-sum test, as applicable.